SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2190792

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2190792

Vascular Closure Device Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

PUBLISHED:
PAGES: 191 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 6050
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The vascular closure device market reached USD 1.85 billion in 2025 and is projected to grow at 5.4% CAGR from 2026 to 2035. The market is expected to cross USD 3.12 billion valuation by 2035. Access management requirements span complex hospital interventions and a growing base of cardiac procedures in ambulatory settings.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$1.85 Billion
Forecast Value$3.12 Billion
CAGR5.4%

Structural heart interventions and high-acuity catheterization make closure part of procedural planning. Larger access requirements increase demand for active systems that support predictable recovery and efficient catheterization-laboratory operation. Operators consider sheath compatibility, familiar clinical performance, and established training rather than deployment speed alone. Expanding cardiovascular infrastructure in lower- and middle-income markets creates another route to purchasing. New catheterization capacity can convert disease burden into additional procedures and repeated device use. Manufacturers need distribution, clinician education, and regulatory execution suited to facilities with different levels of capability. Ambulatory cardiac coverage also changes the buying environment. Centers with leaner operating models place weight on reliable closure, standardized protocols, and recovery processes that fit outpatient care. These requirements create a commercial opportunity for cost-effective products aligned with ambulatory workflows. The drivers therefore combine greater procedural complexity with wider access and a shift in care location. Suppliers must address both specialized structural-heart requirements and routine closure in settings where staffing, recovery arrangements, and purchasing economics differ from those of traditional hospital catheterization units.

Based on product type, active vascular closure devices have projected revenue of USD 2.16 billion by 2035. Femoral access management creates requirements for controlled closure across complex arterial procedures. Product selection reflects the clinical demands of those interventions and the operator's need for predictable performance. The category therefore links device design with the practical management of access sites within established procedural and recovery protocols.

By End Use, hospitals have projected revenue of USD 2.10 billion by 2035. Complex catheterization, electrophysiology, and structural-heart work are concentrated in institutions with specialist teams and formal closure routines. Broad formularies support access to multiple products. These facilities provide a substantial procurement base where device selection can reflect the range of clinical procedures undertaken and the technical support available to their operators.

The North America vascular closure device market has projected revenue of USD 1.21 billion by 2035. Extensive catheterization infrastructure, established structural-heart practice, and movement toward ambulatory care support demand. Clinical evidence is particularly relevant to procurement in this environment. Suppliers must address sophisticated institutional evaluation while supporting products used across both high-acuity interventions and outpatient procedures with different operating and recovery requirements.

Abbott Vascular held over 32% market share in 2025. It competes where physician familiarity, evidence, regulatory approvals, and performance across arterial and venous sites shape purchasing. Comprehensive access-management support also matters to hospitals and ambulatory providers. Major manufacturers therefore benefit from clinical relationships and the ability to support product use within established procedural routines, rather than device functionality considered separately from the intervention.

Some of the major players in this market are Terumo, Haemonetics, Cordis, Teleflex, Medtronic, Ensite Vascular, Meril Life Sciences, Merit Medical, Rex Medical, Transluminal Technologies, Tricol Biomedical, TZ Medical, Vasorum, and Vivasure Medical. Established suppliers combine product portfolios with regional access and focused applications. Emerging companies pursue closure mechanisms and biomaterials suited to evolving arterial and venous requirements, including larger access sites. Outcomes, deployment simplicity, and operator confidence influence competitive differentiation alongside technical innovation. Manufacturers also need to support increasingly complex cardiovascular procedures through the practical adoption of their systems. The five largest participants collectively accounted for approximately 74.0% of worldwide revenue in 2025. This concentration leaves opportunities for specialists whose technologies or regional capabilities address defined needs within the wider access-management workflow, particularly as procedural settings and clinical requirements continue to diversify.

Product Code: 1967

Table of Contents

Chapter 1. Research Methodology

  • 1.1 Research approach
  • 1.2 Quality Commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research Trail & Confidence Scoring
    • 1.3.1 Research Trail Components
    • 1.3.2 Scoring Components
  • 1.4 Data Collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation
  • 1.7 Forecast model
    • 1.7.1 Quantified market impact analysis
      • 1.7.1.1 Mathematical impact of growth parameters on forecast
  • 1.8 Research transparency addendum
    • 1.8.1 Source attribution framework
    • 1.8.2 Quality assurance metrics
    • 1.8.3 Our commitment to trust

Chapter 2. Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Device type trends
    • 2.2.3 Access trends
    • 2.2.4 End use trends
  • 2.3 TAM analysis, 2027-2035
  • 2.4 CXO perspectives: Strategic imperatives
    • 2.4.1 Key decision points for industry executives
    • 2.4.2 Critical success factors for market players
  • 2.5 Future outlook and strategic recommendations

Chapter 3. Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier Landscape
    • 3.1.2 Profit Margin
    • 3.1.3 Cost structure
    • 3.1.4 Value addition at each stage
    • 3.1.5 Factors affecting the value chain
    • 3.1.6 Disruptions
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing number of patients suffering from cardiovascular diseases
      • 3.2.1.2 Growing geriatric population
      • 3.2.1.3 Technological advancements in vascular closure devices
      • 3.2.1.4 Rising volume of interventional cardiology and radiology procedures
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High risk associated with post-procedural complications
      • 3.2.2.2 Stringent regulatory scenario
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion into emerging markets
      • 3.2.3.2 Development of bioresorbable and next-generation closure devices
  • 3.3 Growth potential analysis
  • 3.4 Pricing Analysis (Driven by Primary Research)
    • 3.4.1 Historical Price Trend Analysis
    • 3.4.2 Pricing Strategy by Player Type (Premium / Value / Cost-plus)
  • 3.5 Reimbursement scenario
  • 3.6 Regulatory landscape
    • 3.6.1 North America
    • 3.6.2 Europe
    • 3.6.3 Asia Pacific
    • 3.6.4 Latin America
    • 3.6.5 Middle East and Africa
  • 3.7 Technology landscape
    • 3.7.1 Current technological trends
    • 3.7.2 Emerging technologies
  • 3.8 Trade Data Analysis (Based on Paid Database)
    • 3.8.1 Import/Export Volume & Value Trends
    • 3.8.2 Key Trade Corridors & Tariff Impact
  • 3.9 Impact of AI & Generative AI on the Market (Driven by Primary Research)
    • 3.9.1 AI-Driven Disruption of Existing Business Models
    • 3.9.2 GenAI Use Cases & Adoption Roadmap by Segment
    • 3.9.3 Risks, Limitations & Regulatory Considerations
  • 3.10 Patent / IP Landscape
  • 3.11 Medical Infrastructure Landscape
  • 3.12 Epidemiology / Disease Burden
  • 3.13 Vascular closure device market, 2022-2035 (Units)
    • 3.13.1 North America
    • 3.13.2 Europe
    • 3.13.3 Asia Pacific
    • 3.13.4 Latin America
    • 3.13.5 Middle East and Africa
  • 3.14 Gap analysis
  • 3.15 Porter's analysis
  • 3.16 PESTEL analysis
  • 3.17 Future market trends

Chapter 4. Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 By Region
      • 4.2.1.1 North America
      • 4.2.1.2 Europe
      • 4.2.1.3 Asia Pacific
      • 4.2.1.4 Latin America
      • 4.2.1.5 Middle East and Africa
    • 4.2.2 Market Concentration Analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Key developments
    • 4.5.1 Mergers & acquisitions
    • 4.5.2 Partnerships & collaborations
    • 4.5.3 New product launches
    • 4.5.4 Expansion plans and funding
  • 4.6 Company tier benchmarking
    • 4.6.1 Tier classification criteria & qualifying thresholds
    • 4.6.2 Tier positioning matrix by revenue, geography & innovation

Chapter 5. Market Estimates and Forecast, By Device Type, 2022-2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Active vascular closure devices
    • 5.2.1 Collagen plug mediated device
    • 5.2.2 Suture-mediated devices
    • 5.2.3 Staple/clip-mediated VCD
  • 5.3 Passive vascular closure devices
    • 5.3.1 Haemostasis pads/patches
    • 5.3.2 Compression devices

Chapter 6. Market Estimates and Forecast, By Access, 2022-2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Femoral
  • 6.3 Radial

Chapter 7. Market Estimates and Forecast, By End Use, 2022-2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Ambulatory surgical centers
  • 7.4 Other end use

Chapter 8. Market Estimates and Forecast, By Region, 2022-2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
    • 8.3.7 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9. Company Profiles

  • 9.1 Global Players
    • 9.1.1 Abbott
    • 9.1.2 Cordis
    • 9.1.3 HAEMONETICS
    • 9.1.4 Medtronic
    • 9.1.5 Teleflex
    • 9.1.6 TERUMO
  • 9.2 Regional Players
    • 9.2.1 Ensite Vascular
    • 9.2.2 Meril
    • 9.2.3 MERIT MEDICAL
    • 9.2.4 Rex Medical
  • 9.3 Emerging Players
    • 9.3.1 Transluminal Technologies
    • 9.3.2 Tricol Biomedical
    • 9.3.3 TZ Medical
    • 9.3.4 Vasorum
    • 9.3.5 Vivasure Medical
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!